2017
Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine
Kushnir VA, Seifer DB, Barad DH, Sen A, Gleicher N. Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. Journal Of Assisted Reproduction And Genetics 2017, 34: 1105-1113. PMID: 28643088, PMCID: PMC5581791, DOI: 10.1007/s10815-017-0977-4.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormonePolycystic ovarian syndromePotential therapeutic applicationsReproductive medicineOnset of menopauseNew potential therapeutic applicationsOvarian follicular developmentTherapeutic applicationsSpecific disease conditionsPromising therapeutic applicationOvarian syndromeOvulation inductionFertility preservationPharmacologic agentsFollicular developmentHormone analogueReproductive tractDisease conditionsTherapeutic usesTGF-beta superfamilyAntagonist functionImportant regulatorDiagnostic purposesGonadal tissueKey regulator
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
2002
Practice patterns among board-certified reproductive endocrinologists regarding high-order multiple gestations: a united states national survey.
Hock DL, Seifer DB, Kontopoulos E, Ananth CV. Practice patterns among board-certified reproductive endocrinologists regarding high-order multiple gestations: a united states national survey. Obstetrics And Gynecology 2002, 99: 763-70. PMID: 11978285, DOI: 10.1016/s0029-7844(02)01950-6.Peer-Reviewed Original ResearchMeSH KeywordsCounselingEndocrinologyFemaleFertilization in VitroHealth SurveysHumansInformed ConsentInsemination, ArtificialOvarian FollicleOvulation InductionPractice Patterns, Physicians'PregnancyPregnancy Reduction, MultifetalPregnancy, High-RiskPregnancy, MultipleReproductive MedicineRisk FactorsSuperovulationSurveys and QuestionnairesUnited StatesConceptsHigh-order multiple gestationsMultiple gestationsOverall pregnancy rateReproductive endocrinologistsIntrauterine inseminationOvulation inductionPractice patternsBoard-certified reproductive endocrinologistsHigher-order pregnanciesCurrent practice managementSurvey response ratePregnancy rateMost physiciansGestationResponse ratePractitioner demographicsEndocrinologistsInformed consentSequelaeIncidencePractice managementRiskInseminationInductionQuestionnairePractice Patterns Among Board-Certified Reproductive Endocrinologists Regarding High-Order Multiple Gestations
Hock D, Seifer D, Kontopoulos E, Ananth C. Practice Patterns Among Board-Certified Reproductive Endocrinologists Regarding High-Order Multiple Gestations. Obstetrics And Gynecology 2002, 99: 763-770. DOI: 10.1097/00006250-200205000-00016.Peer-Reviewed Original ResearchHigh-order multiple gestationsMultiple gestationsOverall pregnancy rateReproductive endocrinologistsIntrauterine inseminationOvulation inductionPractice patternsBoard-certified reproductive endocrinologistsHigher-order pregnanciesCurrent practice managementSurvey response ratePregnancy rateMost physiciansGestationResponse ratePractitioner demographicsEndocrinologistsInformed consentSequelaeMethods QuestionnairesIncidencePractice managementRiskInseminationInductionEarly follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility And Sterility 2002, 77: 468-471. PMID: 11872196, DOI: 10.1016/s0015-0282(01)03201-0.Peer-Reviewed Original ResearchConceptsOvarian responseMIS concentrationsReproductive technology cyclesGreater serum concentrationsGroup of womenOvulation inductionSerum concentrationsMaximum serumRetrospective analysisMAIN OUTCOMESubstance levelsSerum MISSerum samplesMI levelsWomenMature oocytesTechnology cyclesReproductive technologiesOocytesSerumART programsGroupIVFGreater number
1999
Infertility treatment and informed consent: current practices of reproductive endocrinologists.
Houmard BS, Seifer DB. Infertility treatment and informed consent: current practices of reproductive endocrinologists. Obstetrics And Gynecology 1999, 93: 252-7. PMID: 9932565, DOI: 10.1016/s0029-7844(98)00389-5.Peer-Reviewed Original ResearchConceptsOvulation inductionCurrent practice patternsInfertility treatmentOvarian cancerReproductive endocrinologistsInformed consentIntrauterine inseminationPractice patternsMost physiciansBoard-certified reproductive endocrinologistsReproductive technologiesPatients of risksOvarian cancer riskLength of treatmentLogistic regression analysisMajority of physiciansAssisted Reproductive TechnologyInvasive therapyCancer riskVerbal consentPossible associationEndocrinologistsCancerPhysiciansCommon changesInfertility Treatment and Informed Consent
HOUMARD B, SEIFER D. Infertility Treatment and Informed Consent. Obstetrics And Gynecology 1999, 93: 252-257. DOI: 10.1097/00006250-199902000-00018.Peer-Reviewed Original ResearchOvulation inductionCurrent practice patternsInfertility treatmentOvarian cancerReproductive endocrinologistsInformed consentIntrauterine inseminationPractice patternsMost physiciansBoard-certified reproductive endocrinologistsReproductive technologiesPatients of risksOvarian cancer riskLength of treatmentLogistic regression analysisMajority of physiciansAssisted Reproductive TechnologyInvasive therapyCancer riskVerbal consentPossible associationCancerEndocrinologistsPhysiciansCommon changes
1997
Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction
Friedman C, Danforth D, Herbosa-Encarnacion C, Arbogast L, Alak B, Seifer D. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertility And Sterility 1997, 68: 607-612. PMID: 9341598, DOI: 10.1016/s0015-0282(97)00278-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingCobaltCohort StudiesCorpus LuteumEndothelial Growth FactorsFemaleFollicular FluidGranulosa CellsHumansHypoxiaLymphokinesMaternal AgeMiddle AgedOsmolar ConcentrationOvulation InductionPregnancyPregnancy, High-RiskRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsAdvanced reproductive ageVascular endothelial growth factor/vascular permeability factorVascular permeability factorReproductive ageFollicular fluidFactor concentrationsPermeability factorFollicular fluid vascular endothelial growth factor concentrationsGranulosa cellsVascular endothelial growth factor concentrationsYoung womenRetrospective cohort studyReproductive-age womenUniversity Teaching HospitalPg/mLGrowth factor concentrationsCohort studyIVF-ETOvulation inductionHCG administrationAge womenCobalt chlorideTeaching hospitalMAIN OUTCOMEFollicular aspirationDay 3 serum inhibin-B is predictive of assisted reproductive technologies outcome
Seifer D, Lambert-Messerlian G, Hogan J, Gárdiner A, Blazar A, Berk C. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility And Sterility 1997, 67: 110-114. PMID: 8986693, DOI: 10.1016/s0015-0282(97)81865-1.Peer-Reviewed Original ResearchConceptsClinical pregnancy rateNumber of oocytesSerum inhibin B concentrationPg/mLInhibin B concentrationsSerum inhibinPregnancy ratePg/Clinical pregnancyOvulation inductionSerum E2Poor responseCancellation rateDay 3 serum FSHAssisted reproductive technology cyclesGnRH agonist suppressionInhibin B valuesReproductive technology cyclesDay of hCGSpontaneous abortion rateAcademic clinical practiceReproductive technologiesSerum FSHOdds ratioE2 response
1996
Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve
Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 736-739. PMID: 8636296, DOI: 10.1210/jcem.81.2.8636296.Peer-Reviewed Original ResearchConceptsDay 3 serum FSHLuteinized granulosa cellsHigh FSH groupDimeric inhibinSerum FSHFSH groupPg/Granulosa cellsFSH levelsOvarian reserveOvulation inductionProgesterone concentrationsDay 3 serum FSH levelsCultured luteinized granulosa cellsDimeric inhibin productionLow FSH groupSerum FSH levelsFertilization-embryo transferHigher FSH levelsReproductive technology programGranulosa cell levelTotal inhibinInhibin concentrationsInhibin productionProspective study
1992
Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen
Seifer DB, Honig J, Penzias AS, Lavy G, Nadkarni PM, Jones EE, DeCherney AH, Flynn SD. Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 636-640. PMID: 1639962, DOI: 10.1210/jcem.75.2.1639962.Peer-Reviewed Original ResearchConceptsHuman menopausal gonadotropinOvulation induction regimenGreater proliferative indexInduction regimenLeuprolide acetateProliferative indexGranulosa cellsGroup IGroup IIGroup IIIAmpules of hMGFunction of ageFlow cytometryDay of hCGProspective cohort studyGroup of patientsHuman granulosa cellsChronological ageMenopausal gonadotropinCohort studyOvulation inductionSerum FSHSignificant independent influenceOutcome measuresWomen's age